Aims to Speed Up Medical Device Approvals Amid Patient Access Concerns
Commissioner Ursula von der Leyen, speaking for the European Commission, aims to tackle the bottlenecks in European Union medical device approvals that delay patient access to vital technologies. By promising legislative and procedural reforms, von der Leyen seeks to balance high safety standards with quicker market access for longstanding devices like widely used hip implants. This development is likely to stir responses from manufacturers eager for faster CE marking, regulatory bodies pressed for resources, and patients awaiting critical treatments.
Response to Parliament's Inquiry from Cynthia Ní Mhurchú (Renew)
This statement answers a 2026 parliamentary question posed by Renew MEP Cynthia Ní Mhurchú, who raised concerns about delays in the Medical Device Regulation (MDR) application slowing access to established medical technologies. The Commission’s reply clarifies current and upcoming actions addressing those delays.
Concrete Proposals, Targets, and Deadlines in the Commission's Response
The Commission outlines concrete steps, including a December 2025 legislative proposal for MDR revision focused on simplification and competitiveness, an April 2026 Implementing Regulation setting maximum timelines for notified body certifications, and March 2026 Delegated Regulations easing requirements for well-established technologies. These initiatives have explicit deadlines and procedural commitments to improve predictability and speed.
Streamlining EU Medical Device Regulation While Upholding Safety
The Commission’s orientation leans toward making MDR and related regulations more streamlined and less burdensome, aiming to reduce processing time without compromising patient safety. This shifts policy toward accelerating internal market competitiveness and supporting innovation, emphasizing a balance between regulatory rigor and reduced administrative delays.
Trade-Offs Between Speed, Safety, and Administrative Burden
Manufacturers may benefit from quicker certification and simplified rules, enhancing competitiveness but needing to adapt to change. Notified bodies face clearer timelines but may encounter increased pressure to meet deadlines. Patients stand to gain timely access to critical devices, though safety standards remain firmly emphasized. National authorities and regulatory bodies will need to enforce new timelines and monitor compliance, implicating resource allocation and oversight intensity.
Expected Institutional Follow-Up and Political Signals
The Commission’s detailed response sets the stage for prompt adoption of the legislative proposal by the European Parliament and Council, with scrutiny ongoing for delegated acts until June 2026. The ongoing regulatory adjustments signal a priority shift toward efficient market access and patient-centric regulatory management within the EU health ecosystem.
← Atlas › News › Health & Lifestyle